SP-303T Applied to the Skin of Patients With Herpes Simplex Virus (HSV) Infection and AIDS Who Have Not Had Success With Acyclovir
Herpes Simplex, HIV Infections
About this trial
This is an interventional treatment trial for Herpes Simplex focused on measuring Herpes Simplex, HIV-1, Acquired Immunodeficiency Syndrome, Antiviral Agents, Administration, Topical
Eligibility Criteria
Inclusion Criteria Patients must have: HIV-1 infection. AIDS. Chronic mucocutaneous herpes simplex virus (HSV) infection, with one or more lesions unresponsive to oral acyclovir therapy. No uncontrolled infections other than HSV. Sufficient mental status to understand the purpose of the study and to comply with study requirements. Sufficient general health to be an outpatient and to come to the clinic for required follow-up visits. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: Known hypersensitivity or allergy to citrus fruits, black currant berries, and rose hips. Any disease condition that, in the opinion of the investigator, would interfere with evaluation of the study drug, affect patient compliance, or place the patient at increased risk. Concurrent Medication: Excluded: Other unapproved investigational new drugs. Concurrent other therapy for herpes simplex virus (HSV) infection or medications with known activity against HSV. Required: A minimum of 10 days of prior oral acyclovir (at least 1 g daily) or 10 days of prior intravenous acyclovir (15 mg/kg daily).
Sites / Locations
- UCSF - San Francisco Gen Hosp
- TheraFirst Med Ctrs Inc
- Saint Luke's - Roosevelt Hosp Ctr
- Univ of Utah School of Medicine